Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 8 Issue 8, August 2009

In This Issue

Top of page ⤴

Editorial

Top of page ⤴

News and Analysis

Top of page ⤴

News Feature

Top of page ⤴

News in Brief

Top of page ⤴

Biobusiness Briefs

Top of page ⤴

News and Analysis

Top of page ⤴

Patent Watch

Top of page ⤴

An Audience With

  • Millennium's Chief Scientific Officer discusses the company's approach to anticancer drug development.

    • Bethan Hughes
    An Audience With
Top of page ⤴

From the Analyst's Couch

Top of page ⤴

Fresh from the Pipeline

    • Jalal K. Ghali
    • Bashar Hamad
    • Peter Kirkpatrick
    Fresh from the Pipeline
Top of page ⤴

Research Highlight

Top of page ⤴

In Brief

Top of page ⤴

Opinion

  • Here, Kenakin discusses how the efficacy of drugs that act at seven-transmembrane receptors is linked to the particular pharmacological assay used to observe the effects of the drug, and highlights how a return to whole–system assays is adding value to the drug discovery process.

    • Terry P. Kenakin
    Opinion
Top of page ⤴

Review Article

  • The phosphoinositide 3-kinase (PI3K) signal transduction pathway is often inappropriately activated in human cancer and is crucial for cancer cell growth and survival. Liu and colleagues discuss key therapeutic targets in the PI3K pathway and agents that are currently in development, and consider the associated challenges and possible approaches to overcome them.

    • Pixu Liu
    • Hailing Cheng
    • Jean J. Zhao
    Review Article
  • Immune tolerance might be therapeutically manipulated to restore normal immunity in allergic disease. This Review highlights current knowledge of immunomodulatory therapies for the manipulation of immune tolerance and discusses recent approaches to improve allergen-specific immunotherapy.

    • Mübeccel Akdis
    • Cezmi A. Akdis
    Review Article
  • Cell surface carbohydrates and carbohydrate-binding proteins mediate many key recognition events. This article reviews current progress in the development of glycomimetics and the opportunities and challenges presented by this relatively untapped source of therapeutics.

    • Beat Ernst
    • John L. Magnani
    Review Article
Top of page ⤴

Careers and Recruitment

Top of page ⤴

Corrigendum

Top of page ⤴

Search

Quick links